NCT04281992 is a Phase 1, PHASE2 clinical trial of AUP1602-C in Diabetic Foot Ulcer, sponsored by Aurealis Oy.

Who is sponsoring NCT04281992?

NCT04281992 is sponsored by Aurealis Oy.

What drugs are being tested in NCT04281992?

Interventions in NCT04281992: AUP1602-C.

What condition does NCT04281992 study?

NCT04281992 studies Diabetic Foot Ulcer.

Is NCT04281992 still recruiting?

NCT04281992 is currently completed. Last updated 28 September 2023.

Last reviewed 2023-09-28 · How we verify

NCT04281992

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Treatment of Diabetic Foot Ulcers With AUP1602-C

Completed Phase 1, PHASE2 Last updated 28 September 2023

What this trial tests

Phase 1, PHASE2 trial testing AUP1602-C in Diabetic Foot Ulcer in 26 participants. Completed in 20 March 2023.

Timeline

28 January 2020

Primary endpoint
20 March 2023

20 March 2023

Quick facts

Lead sponsor	Aurealis Oy
Phase	Phase 1, PHASE2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	26
Start date	28 January 2020
Primary completion	20 March 2023
Estimated completion	20 March 2023
Sites	2 locations across Germany, Poland

Drugs / interventions tested

AUP1602-C — full drug profile →

Conditions studied

Diabetic Foot Ulcer — all drugs for Diabetic Foot Ulcer →

Sponsor

Aurealis Oy — full company profile →

Who can join

Adults 18 to 80, any sex, with Diabetic Foot Ulcer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a two-part phase 1/2A study performed in diabetic foot ulcer (DFU) patients with chronic non-healing wounds to investigate the safety and efficacy of AUP1602-C.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Breakthrough treatments for accelerated wound healing.
Freedman BR, Hwang C, Talbot S, Hibler B, et al · · 2023 · cited 227× · PMID 37196080 · DOI 10.1126/sciadv.ade7007
Engineered bacteria to accelerate wound healing: an adaptive, randomised, double-blind, placebo-controlled, first-in-human phase 1 trial.
Öhnstedt E, Vågesjö E, Fasth A, Lofton Tomenius H, et al · · 2023 · cited 26× · PMID 37251631 · DOI 10.1016/j.eclinm.2023.102014
Multi-target gene therapy AUP1602-C to improve healing and quality of life for diabetic foot ulcer patients: a phase I, open-label, dose-finding study.
Schindler C, Mikosiński J, Mikosiński P, Kärkkäinen HR, et al · · 2024 · cited 9× · PMID 39838970 · DOI 10.1177/20420188241294134
RJX Improves Wound Healing in Diabetic Rats.
Uckun FM, Orhan C, Tuzcu M, Durmus AS, et al · · 2022 · cited 7× · PMID 35721744 · DOI 10.3389/fendo.2022.874291
Immunomodulatory Mechanisms of Chronic Wound Healing: Translational and Clinical Relevance.
Riaz M, Iqbal MZ, Klar AS, Biedermann T. · · 2025 · cited 1× · PMID 41127507 · DOI 10.1002/mco2.70378
Microbial allies in skin trauma recovery: from immune modulation to engineered probiotic therapeutics.
Wang AYL, Aviña AE, Liu YY, Kao HK. · · 2026 · PMID 41550964 · DOI 10.1093/burnst/tkaf068

Verify or expand the search:

Other trials of AUP1602-C

Trials testing the same drug.

NCT06111183 — Evaluation of AUP12602-C as New Topical Treatment for DFUs (DIAMEND STUDY) · Phase 2 · completed

Other recruiting trials for Diabetic Foot Ulcer

Currently open trials in the same condition.

NCT07161830 — Evaluating the Efficacy of OCM™ (Omeza® Complete Matrix) in the Treatment of Diabetic Foot Ulcers · NA · recruiting
NCT07396376 — Evaluation of ELU42 Topical Spray for the Treatment of Diabetic Foot Ulcers · Phase 1, PHASE2 · recruiting
NCT07291817 — Intermittent Negative Pressure for Patients With Diabetic Foot Ulcers (INPRESS) Study · NA · recruiting
NCT07209358 — EDX110 Randomized Control Trial for Treatment of DFUs · NA · recruiting
NCT06938685 — Evaluating the Efficacy NeoThelium FT in the Treatment of Diabetic Foot Ulcers · NA · recruiting

Other Aurealis Oy trials

Trials by the same sponsor.

NCT06111183 — Evaluation of AUP12602-C as New Topical Treatment for DFUs (DIAMEND STUDY) · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04281992 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Aurealis Oy
Last refreshed: 28 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04281992.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing